Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06040541
This study is recruiting at 17 US sites in 11 states, according to its ClinicalTrials.gov record last updated .
Summary
This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Non-small Cell Lung Cancer (NSCLC)
- Colorectal Cancer (CRC)
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Advanced Solid Tumors
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Revolution Medicines, Inc.
- Last updated on ClinicalTrials.gov
- June 3, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- University of California, Davis Comprehensive Cancer Center · Sacramento, CA
Connecticut · 1
- Smilow Cancer Hospital (Yale University) · New Haven, CT
Florida · 2
- Florida Cancer Specialists · Sarasota, FL
- Lee Moffitt Cancer Center · Tampa, FL
Maryland · 1
- Johns Hopkins University · Baltimore, MD
Massachusetts · 2
- Dana-Farber Cancer Institute · Boston, MA
- Massachusetts General Hospital · Boston, MA
New York · 2
- Memorial Sloan Kettering Cancer Center · New York, NY
- NYU Langone · New York, NY
North Carolina · 2
- Duke Cancer Center · Durham, NC
- Carolina BioOncology Institute · Huntersville, NC
Ohio · 1
- The Christ Hospital · Cincinnati, OH
Tennessee · 1
- Sarah Cannon Research Institute · Nashville, TN
Texas · 3
- Sarah Cannon Research Institute at Mary Crowley · Dallas, TX
- University of Texas, MD Anderson Cancer Center · Houston, TX
- START · San Antonio, TX
Virginia · 1
- NEXT Oncology Virginia · Fairfax, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.